10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

C7orf49 Antibody (N-term) Blocking peptide

Synthetic peptide
Catalog # BP13615a

Specification

C7orf49 Antibody (N-term) Blocking peptide - Product Information

Primary Accession Q9BWK5

C7orf49 Antibody (N-term) Blocking peptide - Additional Information

Gene ID 78996

Other Names
Modulator of retrovirus infection homolog, MRI, C7orf49

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13615a was selected from the N-term region of C7orf49. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

C7orf49 Antibody (N-term) Blocking peptide - Protein Information

Name CYREN (HGNC:22432)

Function
Cell-cycle-specific regulator of classical non-homologous end joining (NHEJ) of DNA double-strand break (DSB) repair, which can act both as an activator or inhibitor of NHEJ, depending on the cell cycle phase (PubMed:24610814, PubMed:28959974). Acts as a regulator of DNA repair pathway choice by specifically inhibiting classical NHEJ during the S and G2 phases, thereby promoting error-free repair by homologous recombination during cell cycle phases when sister chromatids are present (PubMed:28959974). Preferentially protects single-stranded overhangs at break sites by inhibiting classical NHEJ, thereby creating a local environment that favors homologous recombination (PubMed:28959974). Acts via interaction with XRCC5/Ku80 and XRCC6/Ku70 (PubMed:28959974). In contrast,

acts as an activator of NHEJ during G1 phase of the cell cycle: promotes classical NHEJ in G1 phase cells via multivalent interactions that increase the affinity of DNA damage response proteins for DSB-associated chromatin. Also involved in immunoglobulin V(D)J recombination (By similarity). May also act as an indirect regulator of proteasome (By similarity).

Cellular Location
[Isoform 1]: Cytoplasm. Nucleus Chromosome. Note=Nuclear localization may depend upon interaction with XRCC5/Ku80 and XRCC6/Ku70 heterodimer (PubMed:24610814). Localizes to DNA damage sites (PubMed:27063109) [Isoform 4]: Cytoplasm. Nucleus Note=Nuclear localization may depend upon interaction with XRCC5/Ku80 and XRCC6/Ku70 heterodimer and increases upon etoposide treatment

C7orf49 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

C7orf49 Antibody (N-term) Blocking peptide - Images

C7orf49 Antibody (N-term) Blocking peptide - Background

C7orf49 may act as a regulator of proteasome (By similarity).

C7orf49 Antibody (N-term) Blocking peptide - References

Agarwal, S., et al. Proc. Natl. Acad. Sci. U.S.A. 103(43):15933-15938(2006)